-
APACC Chair Dr. Junko Tanuma: Tackling HIV Control and Syphilis Resurgence Through Global Collaboration
IDF: As the Conference Chair, could you highlight key agenda innovations? How will Japan facilitate multinational collaboration on HIV and co-infection management across the Asia-Pacific region? Dr. Tanuma: Firstly, I…
-
APACC Global Perspective丨Dr. Thomas Fitzpatrick: How the “Pay-It-Forward” Model Enhances DoxyPEP Accessibility among Key Populations
IDF: In your research conducted in China, how does the Pay-It-Forward mechanism alter the willingness to pay for Doxy-PEP among men who have sex with men (MSM)? Dr. Fitzpatrick: I…
-
Professor Dingwei Ye: A “Precision Breakthrough” in Prostate Cancer Prevention and Treatment in China | 2025 Pujiang Prostate Cancer Congress
As the tides of the Pujiang River surge forward, so too does China’s momentum in prostate cancer innovation. The 2025 Pujiang Prostate Cancer Academic Congress—held jointly with the Annual Meeting of the CSCO Prostate Cancer Committee (CSCO-PC), the Prostate Cancer Conference of the CACA Genitourinary Oncology Committee (CACA-GO), and the Annual Conference of the Chinese…
-
Professor Xiaojie Bian: Innovative Drug Development in Prostate Cancer Is Moving Beyond ARPIs with the Emergence of Multi-Target and Multi-Platform Strategies | 2025 Pujiang Prostate Cancer Congress
The 2025 Pujiang Prostate Cancer Academic Congress, held in conjunction with the CSCO Prostate Cancer Committee (CSCO-PC) Annual Meeting, the CACA Genitourinary Oncology Committee (CACA-GO) Prostate Cancer Meeting, and the Chinese Prostate Cancer Consortium (CPCC) Annual Conference, took place in Shanghai from June 27–28. With the theme “Global Insight · Chinese Practice · Precision Breakthrough,”…
-
2025 ICML | Professor Donglu Zhao: China’s Perspective on DLBCL Treatment Innovation — Novel Strategies, Practical Exploration, and Global Implication
A major highlight of the conference was the special academic session co-organized by the Union for China Lymphoma Investigators (UCLI) and ICML. In this session, Professor Donglu Zhao from the…
-
2025 ICML | Professor Jianyong Li: Dual LYN/BTK Inhibitor DZD8586 Breaks Through Resistance Barriers in CLL/SLL
Hematology Frontier: Recent data show that DZD8586 achieved an objective response rate (ORR) of 84.2% in R/R CLL/SLL patients previously treated with covalent/non-covalent BTK inhibitors or BTK degraders. What are…
-
EHA Spotlight | Profs. Jiang, Chen & Cao: AI-Powered Precision GVHD Prevention with daGOAT
Oncology Frontier – Hematology Frontier: Congratulations on having your study selected for an oral presentation at the congress. The daGOAT model is a key highlight of your research. Could you…
-
Exp Hematol Oncol | Prof. Xiaoxia Hu’s Team Uncovers EBV Risks in the Letermovir Era
Background EBV reactivation occurs in 19.6%–65.0% of allogeneic hematopoietic stem cell transplantation (allo-HCT) recipients and is closely related to post-transplant lymphoproliferative disease (PTLD). Letermovir is effective in reducing CMV reactivation,…
Connecting Medical Expertise through Media